64Z.F KEYMED BIOSCIENCES -0001
- Market cap
- EUR 2.34B
- P/E
- 24.8x
- P/B
- 4.49x
- ROE
- -18.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 64Z.F undervalued?
Graham number64Z.F trades 122.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
KEYMED BIOSCIENCES -0001 fundamental analysis
No fundamental analysis for KEYMED BIOSCIENCES -0001 yet.
KEYMED BIOSCIENCES -0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About KEYMED BIOSCIENCES -0001
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis; CMG901/AZD0901, an antibody drug conjugate for treatment of advanced solid tumo…
Full company profileKEYMED BIOSCIENCES -0001 financial statements
KEYMED BIOSCIENCES -0001 annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 110M | 100M | 354M | 428M | 716M |
| Gross Profit | 93.1M | 97.5M | 317M | 416M | 628M |
| Operating Income | -371M | -478M | -435M | -586M | -548M |
| EBITDA | - | -259M | -270M | -397M | -406M |
| Net Income | -3.89B | -308M | -359M | -515M | -523M |
| EPS | -14 | -1.11 | -1.30 | -1.87 | -1.77 |
| Balance Sheet | |||||
| Total Assets | 3.93B | 3.93B | 3.88B | 3.77B | 4.22B |
| Total Liabilities | 289M | 593M | 896M | 1.29B | 1.44B |
| Shareholders' Equity | 3.65B | 3.34B | 2.99B | 2.47B | 2.77B |
| Cash & Short-term Investments | 1.52B | 604M | 851M | 418M | 503M |
| Cash Flow | |||||
| Operating Cash Flow | -215M | -402M | -304M | -790M | -712M |
| Capital Expenditure | 173M | 280M | 383M | 214M | 336M |
| Free Cash Flow | -387M | -681M | -686M | -1.00B | -1.05B |
| Ratios | |||||
| ROE | -106.5% | -9.2% | -12.0% | -20.8% | -18.8% |
| ROA | -98.8% | -7.8% | -9.3% | -13.7% | -12.4% |
| Net Profit Margin | -3,525.3% | -307.9% | -101.5% | -120.3% | -73.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
KEYMED BIOSCIENCES -0001 dividends
KEYMED BIOSCIENCES -0001 has not paid dividends in the last 5 fiscal years.
Who owns KEYMED BIOSCIENCES -0001
- Insiders 25.16%
- Institutions 32.46%
- Public & others 42.38%
- Shares outstanding 295M
- Free float 219M
KEYMED BIOSCIENCES -0001 company profile
- Company name
- KEYMED BIOSCIENCES -0001
- Ticker
- 64Z.F
- ISIN
- KYG5252B1023
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,768
- Fiscal year end
- December
- Address
- No. 669 Fenghuang Road, Chengdu, China, 610219
- Phone
- 86 28 8861 0620
- Website
- keymedbio.com
About KEYMED BIOSCIENCES -0001
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom. The company develops Kangyueda for the treatment of moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps, and seasonal allergic rhinitis; CMG901/AZD0901, an antibody drug conjugate for treatment of advanced solid tumors; CM512, a TSLP x IL-13 bispecific antibody in Phase I clinical study; and CM518D1, an antibody drug conjugate drug in open-label Phase I/II clinical trial. It is also developing CM336, a CMA x CD3 bispecific antibody in an open-label Phase I/II clinical study for the treatment of patients with relapsed or refractory multiple myeloma; CM313 in Phase II clinical study in subjects with primary immune thrombocytopenia; CM383, an Aß protofibrils antibody in Phase Ib clinical study; and CM559, a N3pG Aß antibody in Phase I clinical study. In addition, the company is involved in the development of CM350, a GPC3 x CD3 bispecific antibody in Phase I/II clinical study; CM326, a TSLP antibody; CM355/ICP-B02/PRO-203, a CD20 x CD3 bispecific antibody; and CM369/ICP-B05, an anti-C-C motif chemokine receptor 8 monoclonal antibody. It has an out-licence agreement with Belenos Biosciences, Inc.; Platina Medicines Ltd; Prolium Biosciences, Inc.; and Timberlyne Therapeutics, Inc. The company was formerly known as 2Health Biosciences, Inc. Keymed Biosciences Inc. was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.
KEYMED BIOSCIENCES -0001 management
5- Dr. Bo Chen Ph.D.Executive Chairman & CEO · born 1975
- Dr. Gang XuSenior VP & Executive Director · born 1975
- Dr. Changyu WangSenior VP & Executive Director · born 1966
- Dr. Qian JiaSenior Vice President · born 1965
- Ms. Pak Yu Tam A.C.I.S., A.C.S.Joint Company Secretary